Evidence map›Paper›PMID 29497929›Full record

ArticleJournal of gastrointestinal cancer2019

Prognostic Value of Cyclin D1 and CD44 Expression in Gastric Adenocarcinoma.

Hanaa M Ibrahim, Abeer M AbdElbary, Salem Y Mohamed, Amira Elwan, Mohamed I Abdelhamid, Amr Ibrahim

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.7field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Increased CD44 Expression and MEK Activity Predict Worse Prognosis in Gastric Adenocarcinoma Patients Undergoing Gastrectomy.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2021
    Article
  12. Review
  13. Article
  14. CD44 as a tumor biomarker and therapeutic target.Experimental hematology & oncology · 2020
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Immunoexpression of E-cadherin, CD44 and Claudin 7 in gastric adenocarcinomas.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Hanaa M IbrahimPathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Abeer M AbdElbaryPathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Salem Y MohamedInternal Medicine Department, Gastroenterology and Hepatology Unit, Faculty of Medicine, Zagazig University, Zagazig, Egypt. salemyousefmohamed@gmail.com.ORCID http://orcid.org/0000-0003-2917-4293
Amira ElwanClinical Oncology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Mohamed I AbdelhamidGeneral Surgery Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Amr IbrahimGeneral Surgery Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Zagazig University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWorldwide, gastric carcinoma (GC) is the 5th most common malignancies in both sexes representing 6.8% of the total fatalities and is the 3rd leading cause of cancer death representing 8.8% of total fatalities. In Egypt, GC considers the 12th leading cause of cancer death representing 2.2% of the total cancer mortality. A growing body of evidence supports that cancer stem cells (CSCs) are resistant to chemotherapy or radiation, and the cell adhesion molecule CD44 has been identified as a cell surface marker associated with cancer stem cell in several types of tumors including gastric cancer. CD44 regulates gastric stem cell proliferation by increasing cyclin D1 expression which represents an important regulatory protein in the cell cycle transition from G1 phase to S phase. This study aimed to investigate whether cyclin D1 and CD44 can be used as prognostic indicators in gastric cancer. MATERIAL AND

methodsForty formalin-fixed and paraffin-embedded gastric tissues, obtained from patients who underwent endoscopic resection or surgical resection, constituted the group of our study. The immunohistochemical expression of cyclin D1 and CD44 was examined and correlated with clinical-pathological parameters and outcome of the patients.

resultsOverexpression of CD44 and cyclin D1 was noted (in of 55 and 50% respectively). Cyclin D1 and CD44 positive expressions in GC were positively correlated with tumor differentiation (p = 0.020, p = 0.004 respectively), TNM stage (p < 0.001 for both), poor survival (p < 0.001 for both), and with increased rate of recurrence (p = 0.020, p = 0.005 respectively).

conclusionCD44 and cyclin D1 were associated with poor prognosis in gastric cancer, and so, they comprise an attractive target for anticancer drug development.

Indexed as

AdenocarcinomaAdultBiomarkers, TumorCase-Control StudiesCyclin D1FemaleFollow-Up StudiesHumansHyaluronan ReceptorsMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisStomach NeoplasmsSurvival RateBiomarkers, TumorCCND1 protein, humanCD44 protein, humanCyclin D1Hyaluronan ReceptorsCancer stem cellsCD44Cyclin D1Gastric carcinoma

Identifiers

PMID29497929
OpenAlexW2790770366

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.